Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5432352 | 0.90 | GAA (0.82) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5426846 | 0.89 | GAA (0.68) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5426838 | 0.87 | MEN1 (0.87) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5426774 | 0.87 | GAA (0.81) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5426953 | 0.85 | GAA (0.77) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5430094 | 0.84 | GAA (0.72) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5431948 | 0.82 | GAA (0.72) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5434608 | 0.81 | GAA (0.67) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5431908 | 0.80 | GAA (0.66) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5435254 | 0.79 | GFER (0.78) | GAAALDH1A1RECQLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | GAA 174/4885ALDH1A1 151/4885RECQL 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.